Goldman Sachs’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-664,386
| Closed | -$2.46M | – | 6653 |
|
|
2017
Q4 | $2.46M | Buy |
664,386
+616,992
| +1,302% | +$2.53M | ﹤0.01% | 3613 |
|
|
2017
Q3 | $193K | Buy |
47,394
+27,268
| +135% | +$104K | ﹤0.01% | 5775 |
|
|
2017
Q2 | $75K | Sell |
20,126
-185,052
| -90% | -$734K | ﹤0.01% | 6239 |
|
|
2017
Q1 | $849K | Buy |
205,178
+185,081
| +921% | +$778K | ﹤0.01% | 4533 |
|
|
2016
Q4 | $87K | Sell |
20,097
-42,321
| -68% | -$274K | ﹤0.01% | 6199 |
|
|
2016
Q3 | $614K | Buy |
62,418
+11,689
| +23% | +$82.9K | ﹤0.01% | 4846 |
|
|
2016
Q2 | $287K | Buy |
50,729
+41,622
| +457% | +$283K | ﹤0.01% | 5375 |
|
|
2016
Q1 | $69K | Sell |
9,107
-3,198
| -26% | -$24.6K | ﹤0.01% | 6267 |
|
|
2015
Q4 | $164K | Buy |
12,305
+7,787
| +172% | +$134K | ﹤0.01% | 5852 |
|
|
2015
Q3 | $74K | Sell |
4,518
-8,236
| -65% | -$169K | ﹤0.01% | 6640 |
|
|
2015
Q2 | $286K | Buy |
12,754
+9,025
| +242% | +$143K | ﹤0.01% | 5789 |
|
|
2015
Q1 | $36K | Buy |
+3,729
| New | +$36.6K | ﹤0.01% | 6788 |
|
|
2014
Q4 | – | Sell |
-6,832
| Closed | -$79K | – | 7443 |
|
|
2014
Q3 | $79K | Buy |
6,832
+1,554
| +29% | +$23.7K | ﹤0.01% | 6679 |
|
|
2014
Q2 | $103K | Sell |
5,278
-758
| -13% | -$13.4K | ﹤0.01% | 6539 |
|
|
2014
Q1 | $109K | Buy |
6,036
+2,545
| +73% | +$41.8K | ﹤0.01% | 6371 |
|
|
2013
Q4 | $37K | Sell |
3,491
-38,979
| -92% | -$436K | ﹤0.01% | 6473 |
|
|
2013
Q3 | $525K | Sell |
42,470
-1,054
| -2% | -$11.1K | ﹤0.01% | 5127 |
|
|
2013
Q2 | $410K | Buy |
+43,524
| New | +$559K | ﹤0.01% | 5104 |
|
Goldman Sachs's CASC Position: Q1 2018 in Review
Goldman Sachs sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 664,386 shares — an estimated $2.46M sold.
Goldman Sachs first reported a position in CASC in Q2 2013 and held it in 18 quarters. The position peaked at $2.46M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Goldman Sachs reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Goldman Sachs sold 664,386 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2.46M.
- Goldman Sachs first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
- Goldman Sachs's Cascadian Therapeutics, Inc. position peaked at $2.46M in Q4 2017.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Goldman Sachs's 13F filing for Q1 2018, filed 15 May 2018.